Targeting the VEGF signaling pathway in cancer therapy

Bibliography

• Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803
   PubMed Web of Science ®Google Scholar
• FDA Approval for Bevacizumab.Washington, DC: FDA 2011. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab [Last accessed 25 November 2011]
   Google Scholar
• Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40
   PubMedGoogle Scholar
• Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 1975;82:96-100
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
   PubMed Web of Science ®Google Scholar
• Senger DR, Galli SJ, Dvorak AM, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5
   PubMed Web of Science ®Google Scholar
• Saranadasa M, Wang ES. Vascular endothelial growth factor inhibition: conflicting roles in tumor growth. Cytokine 2011;53:115-29
   Google Scholar
• Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-14
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 2009;20:158-63
   PubMed Web of Science ®Google Scholar
• Epstein RJ. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev 2007;26:443-52
   PubMedGoogle Scholar
• Soker S, Takashima S, Miao HQ, Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-45
   PubMed Web of Science ®Google Scholar
• Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005;438:946-53
   PubMed Web of Science ®Google Scholar
• Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2009;2:re1
   PubMed Web of Science ®Google Scholar
• Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010;20:51-6
   PubMed Web of Science ®Google Scholar
• Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66-70
   PubMed Web of Science ®Google Scholar
• Shalaby F, Rossant J, Yamaguchi TP, Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62-6
   PubMed Web of Science ®Google Scholar
• Ferrara N, Carver-Moore K, Chen H, Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4
   PubMed Web of Science ®Google Scholar
• Millauer B, Shawver LK, Plate KH, Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-9
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-91
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103
   PubMed Web of Science ®Google Scholar
• Scaldaferri F, Vetrano S, Sans M, VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009;136:585-95. e5
   PubMed Web of Science ®Google Scholar
• Yoo SA, Kwok SK, Kim WU. Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm 2008;2008:129873
   PubMed Web of Science ®Google Scholar
• Luo J, Xiong Y, Han X, Lu Y. VEGF non-angiogenic functions in adult organ homeostasis: therapeutic implications. J Mol Med (Berl) 2011;89:635-45
   PubMed Web of Science ®Google Scholar
• Lichtenberger BM, Tan PK, Niederleithner H, Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 2010;140:268-79
   PubMed Web of Science ®Google Scholar
• Waldner MJ, Wirtz S, Jefremow A, VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med 2010;207:2855-68
   PubMed Web of Science ®Google Scholar
• Xue Y, Religa P, Cao R, Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci USA 2008;105:18513-18
   PubMed Web of Science ®Google Scholar
• Cao Y. Off-tumor target–beneficial site for antiangiogenic cancer therapy? Nat Rev Clin Oncol 2010;7:604-8
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307
   PubMed Web of Science ®Google Scholar
• Jin K, Shen Y, He K, Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer? Clin Transl Oncol 2010;12:526-32
   Google Scholar
• Sanofi-aventis and Regeneron Report Positive Phase III mCRC Trial DATA. Paris, France: Sanofi-Aventis,2011. Available from: http://en.sanofi.com/Images/28326_20110426_VELOUR_en.pdf [Last accessed 25 November 2011]
   Google Scholar
• Wick W, Weller M, van den Bent M, Stupp R. Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 2010;28:e188-9. author reply e90-2
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9
   PubMed Web of Science ®Google Scholar
• Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009;15:167-70
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31
   PubMed Web of Science ®Google Scholar
• Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009;5:610-20
   PubMed Web of Science ®Google Scholar
• Keunen O, Johansson M, Oudin A, Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 2011;108:3749-54
   PubMed Web of Science ®Google Scholar
• de Groot JF, Fuller G, Kumar AJ, Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010;12:233-42
   PubMed Web of Science ®Google Scholar
• Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21
   PubMed Web of Science ®Google Scholar
• Zhang D, Hedlund EM, Lim S, Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity. Proc Natl Acad Sci USA 2011;108:4117-22
   Google Scholar
• Cunningham D, Humblet Y, Siena S, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65
   PubMed Web of Science ®Google Scholar
• Ferroni P, Spila A, Martini F, Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancer. Oncology 2005;69:145-53
   Google Scholar
• Otrock ZK, Hatoum HA, Musallam KM, Is VEGF a predictive biomarker to anti-angiogenic therapy? Crit Rev Oncol Hematol 2011;79:103-11
   PubMedGoogle Scholar
• Zhu AX, Sahani DV, Duda DG, Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a Phase II study. J Clin Oncol 2009;27:3027-35
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Chen YH, Parker LM, VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008;14:7871-7
   PubMed Web of Science ®Google Scholar
• Jubb AM, Hurwitz HI, Bai W, Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24:217-27
   PubMed Web of Science ®Google Scholar
• Dowlati A, Gray R, Sandler AB, Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab–an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008;14:1407-12
   PubMed Web of Science ®Google Scholar
• Rini BI, Michaelson MD, Rosenberg JE, Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-8
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95
   PubMed Web of Science ®Google Scholar
• Norden-Zfoni A, Desai J, Manola J, Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007;13:2643-50
   PubMed Web of Science ®Google Scholar
• Sessa C, Guibal A, Del Conte G, Ruegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 2008;5:378-91
   PubMedGoogle Scholar
• Jain RK, Duda DG, Willett CG, Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-38
   PubMed Web of Science ®Google Scholar
• Wedam SB, Low JA, Yang SX, Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-77
   PubMed Web of Science ®Google Scholar
• Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist 2010;15:130-41
   PubMed Web of Science ®Google Scholar
• Osterlund P, Soveri LM, Isoniemi H, Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 2011;104:599-604
   PubMed Web of Science ®Google Scholar
• Dahlberg SE, Sandler AB, Brahmer JR, Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010;28:949-54
   PubMed Web of Science ®Google Scholar
• Rini BI. Biomarkers: hypertension following anti-angiogenesis therapy. Clin Adv Hematol Oncol 2010;8:415-16
   Google Scholar
• Schneider BP, Wang M, Radovich M, Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-8
   PubMed Web of Science ®Google Scholar
• Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988;48:2641-58
   PubMed Web of Science ®Google Scholar
• Baish JW, Jain RK. Cancer, angiogenesis and fractals. Nat Med 1998;4:984
   Google Scholar
• Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94:883-93
   PubMed Web of Science ®Google Scholar
• Lassau N, Lamuraglia M, Chami L, Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 2006;187:1267-73
   PubMed Web of Science ®Google Scholar
• Lassau N, Chami L, Benatsou B, Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment. Eur Radiol 2007;17(Suppl 6):F89-98
   Google Scholar
• Lassau N, Koscielny S, Chami L, Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification–preliminary results. Radiology 2011;258:291-300
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Cats A, Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72
   PubMed Web of Science ®Google Scholar
• Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009;361:98-9
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Bianco R, Damiano V, Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6:3739-47
   PubMed Web of Science ®Google Scholar
• Tonra JR, Deevi DS, Corcoran E, Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006;12:2197-207
   PubMed Web of Science ®Google Scholar
• Punt CJ, Tol J. More is less – combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol 2009;6:731-3
   PubMed Web of Science ®Google Scholar